Rate Video

EHA 2020 | Cytogenetic risk & the impact of daratumumab in myeloma

Luciano Costa • 15 Jun 2020

Multiple Myeloma Antibodies Daratumumab

APOLLO CANDOR CASTOR

Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, highlights results of a meta-analysis determining the impact of daratumumab in the treatment of multiple myeloma according to cytogenetic risk. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

MRD-based response-adapted consolidation in NDMM post-transplant

Real-world data on outcomes of t(11;14) multiple myeloma

Luciano Costa • 6 Dec 2020

Refractory multiple myeloma: analyzing MAMMOTH and STORM

Luciano Costa • 3 Oct 2020

MRD assessment in R/R myeloma treated with VenKd

Luciano Costa • 6 Dec 2020

Related Videos

Addition of daratumumab to R/R myeloma regimens improves outcomes

Saad Usmani • 18 Dec 2020

Bispecific antibodies for myeloma: highlights from ASH 2020

Saad Usmani • 17 Dec 2020

Ide-cel CAR T-cell therapy in newly diagnosed high-risk myeloma

Saad Usmani • 17 Dec 2020

Anti-BCMA CAR T-cell therapy in myeloma: updates from ASH 2020

Saad Usmani • 17 Dec 2020